Edgewise Therapeutics (NASDAQ:EWTX) Reaches New 1-Year High – Here’s Why

Shares of Edgewise Therapeutics, Inc. (NASDAQ:EWTXGet Free Report) reached a new 52-week high on Wednesday . The company traded as high as $30.29 and last traded at $29.98, with a volume of 446638 shares traded. The stock had previously closed at $28.49.

Analysts Set New Price Targets

EWTX has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and issued a $31.00 price target on shares of Edgewise Therapeutics in a research note on Friday, August 16th. Truist Financial upped their target price on shares of Edgewise Therapeutics from $25.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $32.00 price target on shares of Edgewise Therapeutics in a research report on Tuesday, September 17th. JPMorgan Chase & Co. boosted their price objective on Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a report on Monday, August 12th. Finally, Piper Sandler increased their target price on Edgewise Therapeutics from $48.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $35.60.

View Our Latest Stock Report on EWTX

Edgewise Therapeutics Trading Down 1.1 %

The firm has a market cap of $2.81 billion, a P/E ratio of -19.35 and a beta of 0.20. The business’s 50-day moving average is $21.04 and its two-hundred day moving average is $19.14.

Edgewise Therapeutics (NASDAQ:EWTXGet Free Report) last posted its earnings results on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. On average, analysts anticipate that Edgewise Therapeutics, Inc. will post -1.47 earnings per share for the current year.

Insiders Place Their Bets

In related news, CFO R Michael Carruthers sold 125,092 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $28.57, for a total value of $3,573,878.44. Following the sale, the chief financial officer now directly owns 6,904 shares in the company, valued at $197,247.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, General Counsel John R. Moore sold 20,922 shares of the stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $27.63, for a total value of $578,074.86. Following the completion of the transaction, the general counsel now directly owns 3,252 shares in the company, valued at $89,852.76. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO R Michael Carruthers sold 125,092 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $28.57, for a total value of $3,573,878.44. Following the sale, the chief financial officer now directly owns 6,904 shares in the company, valued at approximately $197,247.28. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 278,176 shares of company stock worth $7,893,316. Insiders own 24.11% of the company’s stock.

Hedge Funds Weigh In On Edgewise Therapeutics

Several hedge funds have recently modified their holdings of the company. RA Capital Management L.P. bought a new position in Edgewise Therapeutics during the first quarter valued at about $162,502,000. Novo Holdings A S acquired a new stake in Edgewise Therapeutics in the 2nd quarter valued at about $114,263,000. Baker BROS. Advisors LP boosted its position in shares of Edgewise Therapeutics by 87.6% during the 1st quarter. Baker BROS. Advisors LP now owns 5,840,059 shares of the company’s stock valued at $106,523,000 after purchasing an additional 2,727,273 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Edgewise Therapeutics by 89.0% in the 1st quarter. Vanguard Group Inc. now owns 4,017,433 shares of the company’s stock worth $73,278,000 after purchasing an additional 1,892,053 shares during the last quarter. Finally, Frazier Life Sciences Management L.P. grew its stake in shares of Edgewise Therapeutics by 12.9% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 3,731,067 shares of the company’s stock worth $67,197,000 after purchasing an additional 427,500 shares during the last quarter.

Edgewise Therapeutics Company Profile

(Get Free Report)

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.

Featured Stories

Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.